<?xml version='1.0' encoding='utf-8'?>
<document id="31889141"><sentence text="Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein."><entity charOffset="12-22" id="DDI-PubMed.31889141.s1.e0" text="febuxostat" /><entity charOffset="32-44" id="DDI-PubMed.31889141.s1.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.31889141.s1.e0" e2="DDI-PubMed.31889141.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31889141.s1.e0" e2="DDI-PubMed.31889141.s1.e1" /></sentence><sentence text="Methotrexate (MTX) is an antifolate agent used for the treatment of various malignancies and is eliminated by breast cancer resistance protein (BCRP)"><entity charOffset="0-12" id="DDI-PubMed.31889141.s2.e0" text="Methotrexate" /><entity charOffset="14-17" id="DDI-PubMed.31889141.s2.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.31889141.s2.e0" e2="DDI-PubMed.31889141.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31889141.s2.e0" e2="DDI-PubMed.31889141.s2.e1" /></sentence><sentence text=" Because febuxostat (FBX) is known to inhibit BCRP activity, FBX might exacerbate MTX-related adverse effects"><entity charOffset="9-19" id="DDI-PubMed.31889141.s3.e0" text="febuxostat" /><entity charOffset="21-24" id="DDI-PubMed.31889141.s3.e1" text="FBX" /><entity charOffset="82-84" id="DDI-PubMed.31889141.s3.e2" text="MTX" /><entity charOffset="61-63" id="DDI-PubMed.31889141.s3.e3" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e0" e2="DDI-PubMed.31889141.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e0" e2="DDI-PubMed.31889141.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e0" e2="DDI-PubMed.31889141.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e0" e2="DDI-PubMed.31889141.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e1" e2="DDI-PubMed.31889141.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e1" e2="DDI-PubMed.31889141.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e1" e2="DDI-PubMed.31889141.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e3" e2="DDI-PubMed.31889141.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31889141.s3.e3" e2="DDI-PubMed.31889141.s3.e2" /></sentence><sentence text=" In this study, we examined the drug-drug interaction between FBX and MTX in BCRP-expressing membrane vesicles"><entity charOffset="70-72" id="DDI-PubMed.31889141.s4.e0" text="MTX" /><entity charOffset="62-64" id="DDI-PubMed.31889141.s4.e1" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s4.e1" e2="DDI-PubMed.31889141.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s4.e1" e2="DDI-PubMed.31889141.s4.e0" /></sentence><sentence text=" Moreover, we retrospectively investigated the impact of FBX on MTX-related adverse effects in 38 patients (144 cycles) receiving high-dose MTX therapy (HDMTX)"><entity charOffset="64-66" id="DDI-PubMed.31889141.s5.e0" text="MTX" /><entity charOffset="140-142" id="DDI-PubMed.31889141.s5.e1" text="MTX" /><entity charOffset="155-157" id="DDI-PubMed.31889141.s5.e2" text="MTX" /><entity charOffset="57-59" id="DDI-PubMed.31889141.s5.e3" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s5.e3" e2="DDI-PubMed.31889141.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31889141.s5.e3" e2="DDI-PubMed.31889141.s5.e0" /><pair ddi="true" e1="DDI-PubMed.31889141.s5.e3" e2="DDI-PubMed.31889141.s5.e1" /><pair ddi="true" e1="DDI-PubMed.31889141.s5.e3" e2="DDI-PubMed.31889141.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31889141.s5.e0" e2="DDI-PubMed.31889141.s5.e0" /><pair ddi="true" e1="DDI-PubMed.31889141.s5.e0" e2="DDI-PubMed.31889141.s5.e1" /><pair ddi="true" e1="DDI-PubMed.31889141.s5.e0" e2="DDI-PubMed.31889141.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31889141.s5.e1" e2="DDI-PubMed.31889141.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s5.e1" e2="DDI-PubMed.31889141.s5.e2" /></sentence><sentence text=" The Food and Drug Administration Adverse Event Reporting System (FAERS) database and human hepatocellular carcinoma cell line HepG2 cells were used to evaluate the effects of FBX on MTX-induced hepatotoxicity"><entity charOffset="183-185" id="DDI-PubMed.31889141.s6.e0" text="MTX" /><entity charOffset="176-178" id="DDI-PubMed.31889141.s6.e1" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s6.e1" e2="DDI-PubMed.31889141.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s6.e1" e2="DDI-PubMed.31889141.s6.e0" /></sentence><sentence text=" In the membrane vesicle study, FBX significantly inhibited BCRP-mediated transport of MTX"><entity charOffset="87-89" id="DDI-PubMed.31889141.s7.e0" text="MTX" /><entity charOffset="32-34" id="DDI-PubMed.31889141.s7.e1" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s7.e1" e2="DDI-PubMed.31889141.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s7.e1" e2="DDI-PubMed.31889141.s7.e0" /></sentence><sentence text=" Concomitant FBX significantly increased the incidence of hepatotoxicity, but not of nephrotoxicity and hematological toxicity in patients receiving HDMTX"><entity charOffset="151-153" id="DDI-PubMed.31889141.s8.e0" text="MTX" /><entity charOffset="13-15" id="DDI-PubMed.31889141.s8.e1" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s8.e1" e2="DDI-PubMed.31889141.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s8.e1" e2="DDI-PubMed.31889141.s8.e0" /></sentence><sentence text=" FAERS database analyses revealed that the reporting odds ratio of FBX for MTX-induced hepatotoxicity was 4"><entity charOffset="75-77" id="DDI-PubMed.31889141.s9.e0" text="MTX" /><entity charOffset="67-69" id="DDI-PubMed.31889141.s9.e1" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s9.e1" e2="DDI-PubMed.31889141.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s9.e1" e2="DDI-PubMed.31889141.s9.e0" /></sentence><sentence text="16 (95% CI: 2" /><sentence text="89-5" /><sentence text="98)" /><sentence text=" Co-incubated FBX significantly decreased the cell viability and increased cytotoxicity in MTX-treated HepG2 cells"><entity charOffset="91-93" id="DDI-PubMed.31889141.s13.e0" text="MTX" /><entity charOffset="14-16" id="DDI-PubMed.31889141.s13.e1" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s13.e1" e2="DDI-PubMed.31889141.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s13.e1" e2="DDI-PubMed.31889141.s13.e0" /></sentence><sentence text=" These findings suggest that concomitant FBX enhances MTX-induced hepatotoxicity by inhibiting hepatic BCRP"><entity charOffset="54-56" id="DDI-PubMed.31889141.s14.e0" text="MTX" /><entity charOffset="41-43" id="DDI-PubMed.31889141.s14.e1" text="FBX" /><pair ddi="false" e1="DDI-PubMed.31889141.s14.e1" e2="DDI-PubMed.31889141.s14.e1" /><pair ddi="false" e1="DDI-PubMed.31889141.s14.e1" e2="DDI-PubMed.31889141.s14.e0" /></sentence><sentence text=" These findings provide important information for the safe management of HDMTX therapy in clinical settings"><entity charOffset="75-77" id="DDI-PubMed.31889141.s15.e0" text="MTX" /></sentence><sentence text="" /></document>